Publication: Attainment of LDL-Cholesterol Treatment Goals in Patients With Familial Hypercholesterolemia 5-Year SAFEHEART Registry Follow-Up
dc.contributor.author | Perez-de-Isla, Leopoldo | |
dc.contributor.author | Alonso, Rodrigo | |
dc.contributor.author | Watts, Gerald F. | |
dc.contributor.author | Mata, Nelva | |
dc.contributor.author | Saltijeral-Cerezo, Adriana | |
dc.contributor.author | Muniz, Ovidio | |
dc.contributor.author | Fuentes, Francisco | |
dc.contributor.author | Diaz-Diaz, Jose Luis | |
dc.contributor.author | de-Andres, Raimundo | |
dc.contributor.author | Zambon, Daniel | |
dc.contributor.author | Rubio-Marin, Patricia | |
dc.contributor.author | Barba-Romero, Miguel A. | |
dc.contributor.author | Saenz, Pedro | |
dc.contributor.author | Sanchez-Munoz-Torrero, Juan F. | |
dc.contributor.author | Martinez-Faedo, Ceferino | |
dc.contributor.author | Miramontes-Gonzalez, Jose P. | |
dc.contributor.author | Badimon, Lina | |
dc.contributor.author | Mata, Pedro | |
dc.contributor.authoraffiliation | [Perez de Isla, Leopoldo] Hosp Clin San Carlos, IDISSC, Dept Cardiol, Madrid, Spain | |
dc.contributor.authoraffiliation | [Perez de Isla, Leopoldo] Fdn Hipercolesterolemia Familiar, C Gen Alvarez Castro 14, Madrid 28010, Spain | |
dc.contributor.authoraffiliation | [Alonso, Rodrigo] Fdn Hipercolesterolemia Familiar, C Gen Alvarez Castro 14, Madrid 28010, Spain | |
dc.contributor.authoraffiliation | [Mata, Nelva] Fdn Hipercolesterolemia Familiar, C Gen Alvarez Castro 14, Madrid 28010, Spain | |
dc.contributor.authoraffiliation | [Saltijeral Cerezo, Adriana] Fdn Hipercolesterolemia Familiar, C Gen Alvarez Castro 14, Madrid 28010, Spain | |
dc.contributor.authoraffiliation | [Mata, Pedro] Fdn Hipercolesterolemia Familiar, C Gen Alvarez Castro 14, Madrid 28010, Spain | |
dc.contributor.authoraffiliation | [Alonso, Rodrigo] Clin Las Condes, Santiago, Chile | |
dc.contributor.authoraffiliation | [Watts, Gerald F.] Royal Perth Hosp, Ctr Cardiovasc Med, Lipid Disorders Clin, Perth, WA 6001, Australia | |
dc.contributor.authoraffiliation | [Watts, Gerald F.] Univ Western Australia, Sch Med & Pharmacol, Perth, WA 6009, Australia | |
dc.contributor.authoraffiliation | [Mata, Nelva] Madrid Hlth Author, Dept Epidemiol, Madrid, Spain | |
dc.contributor.authoraffiliation | [Saltijeral Cerezo, Adriana] Hosp Tajo, Dept Cardiol, Madrid, Spain | |
dc.contributor.authoraffiliation | [Muniz, Ovidio] Hosp Virgen Rocio, Dept Internal Med, Seville, Spain | |
dc.contributor.authoraffiliation | [Fuentes, Francisco] Univ Hosp, Dept Internal Med, Cordoba, Spain | |
dc.contributor.authoraffiliation | [Luis Diaz-Diaz, Jose] Hosp Abente & Lago, Dept Internal Med, La Coruna, Spain | |
dc.contributor.authoraffiliation | [de Andres, Raimundo] Fdn Jimenez Diaz, Dept Internal Med, E-28040 Madrid, Spain | |
dc.contributor.authoraffiliation | [Zambon, Daniel] Hosp Clin Barcelona, Dept Endocrinol, Barcelona, Spain | |
dc.contributor.authoraffiliation | [Rubio-Marin, Patricia] Hosp SAS Jerez Frontera, Dept Internal Med, Cadiz, Spain | |
dc.contributor.authoraffiliation | [Barba-Romero, Miguel A.] Complejo Hosp Univ, Dept Internal Med, Albacete, Spain | |
dc.contributor.authoraffiliation | [Saenz, Pedro] Hosp Merida, Dept Internal Med, Extremadura, Spain | |
dc.contributor.authoraffiliation | [Sanchez Munoz-Torrero, Juan F.] Hosp San Pedro Alcantara, Dept Internal Med, Caceres, Spain | |
dc.contributor.authoraffiliation | [Martinez-Faedo, Ceferino] Cent Hosp, Dept Endocrinol, Asturias, Spain | |
dc.contributor.authoraffiliation | [Miramontes-Gonzalez, Jose P.] Univ Hosp, Dept Internal Med, Salamanca, Spain | |
dc.contributor.authoraffiliation | [Badimon, Lina] IIB St Pau, Inst Catalan Ciencias Cardiovasc, Barcelona, Spain | |
dc.contributor.funder | Fundacion Hipercolesterolemia Familiar | |
dc.contributor.funder | Instituto de Salud Carlos III (ISCIII) | |
dc.contributor.funder | Centro Nacional de Investigacion Cardiovascular (CNIC) | |
dc.contributor.funder | Merck Sharp Dohme | |
dc.contributor.funder | AstraZeneca | |
dc.contributor.funder | AMGEN | |
dc.contributor.funder | AEGERION | |
dc.contributor.funder | ISIS | |
dc.contributor.funder | Sanofi | |
dc.contributor.group | SAFEHEART Investigators | |
dc.date.accessioned | 2023-02-12T02:20:54Z | |
dc.date.available | 2023-02-12T02:20:54Z | |
dc.date.issued | 2016-01-05 | |
dc.description.abstract | BACKGROUND Familial hypercholesterolemia (FH) is the most common genetic disorder associated with premature atherosclerotic cardiovascular disease (ASCVD). There are sparse data on attainment of treatment targets; large registries that reflect real-life clinical practice can uniquely provide this information.OBJECTIVES We sought to evaluate the achievement of low-density lipoprotein cholesterol (LDL-C) treatment goals in FH patients enrolled in a large national registry.METHODS The SAFEHEART study (Spanish Familial Hypercholesterolemia Cohort Study) is a large, ongoing registry of molecularly defined patients with heterozygous FH treated in Spain. The attainment of guideline-recommended plasma LDL-C goals at entry and follow-up was investigated in relation to use of lipid-lowering therapy (LLT).RESULTS The study recruited 4,132 individuals (3,745 of whom were >= 18 years of age); 2,752 of those enrolled were molecularly diagnosed FH cases. Mean follow-up was 5.1 +/- 3.1 years; 71.8% of FH cases were on maximal LLT, and an LDL-C treatment target = 18 years of age); 2,752 of those enrolled were molecularly diagnosed FH cases. Mean follow-up was 5.1 +/- 3.1 years; 71.8% of FH cases were on maximal LLT, and an LDL-C treatment target <100 mg/dl was reached by only 11.2% of patients. At follow-up, there was a significant increasein the use of ezetimibe, drug combinations with statins, and maximal LLT. The presence of type 2 diabetes mellitus, adefective allele mutation, ezetimibe use, and the absence of previous ASCVD were predictors of the attainment ofLDL-C goals. CONCLUSIONS Despite the use of intensified LLT, many FH patients continue to experience high plasma LDL-C levelsand, consequently, do not achieve recommended treatment targets. Type of LDL-receptor mutation, use of ezetimibe,coexistent diabetes, and ASCVD status can bear significantly on the likelihood of attaining LDL-C treatment goals. | |
dc.description.version | Si | |
dc.identifier.citation | Perez de Isla L, Alonso R, Watts GF, Mata N, Saltijeral Cerezo A, Muñiz O, et al. Attainment of LDL-Cholesterol Treatment Goals in Patients With Familial Hypercholesterolemia: 5-Year SAFEHEART Registry Follow-Up. J Am Coll Cardiol. 2016 Mar 22;67(11):1278-85 | |
dc.identifier.doi | 10.1016/j.jacc.2016.01.008 | |
dc.identifier.essn | 1558-3597 | |
dc.identifier.issn | 0735-1097 | |
dc.identifier.uri | http://hdl.handle.net/10668/18806 | |
dc.identifier.wosID | 371881400003 | |
dc.issue.number | 11 | |
dc.journal.title | Journal of the american college of cardiology | |
dc.journal.titleabbreviation | J. am. coll. cardiol. | |
dc.language.iso | en | |
dc.organization | Área de Gestión Sanitaria de Jerez, Costa Noroeste y Sierra de Cádiz | |
dc.organization | Hospital Universitario Reina Sofía | |
dc.organization | Hospital Universitario Virgen del Rocío | |
dc.organization | AGS - Jerez, Costa Noroeste y Sierra de Cáidz | |
dc.page.number | 1278-1285 | |
dc.provenance | Realizada la curación de contenido 16/06/2025 | |
dc.publisher | Elsevier | |
dc.relation.publisherversion | https://linkinghub.elsevier.com/retrieve/pii/S0735-1097(16)00229-1 | |
dc.rights.accessRights | Restricted Access | |
dc.subject | Guidance | |
dc.subject | Management | |
dc.subject | Ezetimibe | |
dc.subject | Mortality | |
dc.subject | Efficacy | |
dc.subject | Therapy | |
dc.subject | Disease | |
dc.subject | Cohort | |
dc.subject | Risk | |
dc.subject | Care | |
dc.subject | Área de Gestión Sanitaria de Jerez, Costa Noroeste y Sierra de Cádiz | |
dc.subject | Cardiovascular disease | |
dc.subject | LDL-receptor mutations | |
dc.subject | Lipid-lowering therapy | |
dc.subject | Low-density lipoprotein cholesterol | |
dc.subject.decs | Hipercolesterolemia familiar | |
dc.subject.decs | Colesterol LDL | |
dc.subject.decs | Enfermedad cardiovascular aterosclerótica | |
dc.subject.decs | Terapia hipolipemiante | |
dc.subject.decs | Ezetimiba | |
dc.subject.decs | Diabetes mellitus tipo 2 | |
dc.title | Attainment of LDL-Cholesterol Treatment Goals in Patients With Familial Hypercholesterolemia 5-Year SAFEHEART Registry Follow-Up | |
dc.type | research article | |
dc.volume.number | 67 | |
dc.wostype | Article | |
dspace.entity.type | Publication |
Files
Original bundle
1 - 1 of 1
No Thumbnail Available
- Name:
- RISalud_Accesorestringido.pdf
- Size:
- 93.39 KB
- Format:
- Adobe Portable Document Format